Marcos, gang...put CNJ on your watchlist. May be a great Canadian company to own. finance.yahoo.com
I like the story thats developing. I'm not posting this anywhere else but here... just want to do my bit of contributing to this great thread. Good luck all. And what a great day to be a stockholder, and purchaser!!
I scooped the attached stuff from SH. I bought some today based on the following:
- significant revenue returns for CNJ over the next several years
- revenues from the US government
- current target on CNJ is $13.50
- insider buying
- sexy biotech shaping up
Quotes:
"appears to now place Cangene amongst the highest in ranking of those companies with the ability to produce biological products as a countermeasure to biological terrorism."
"Cangene is begining to carve out a very important niche for itself in its ability to fulfill contract manufacturing requirements for the production of biological products."
"the US government has contracted for the manufacture of 300 million doses of the smallpox vaccine from the Baxter/Acambis/CBL/Cangene partnership."
------------DETAIL - oldest to newest ---------------
Immune globulin in short supply__ Donors get top dollar, plus vaccine__ 07/19/02__ By WILLIAM RABB __ Staff Reporter
As part of a plan to combat possible bioterrorist attacks, a blood products company is paying up to $900 to local volunteers who will get a smallpox vaccine, then donate blood plasma for eight weeks.
Serologicals Corp., an international blood products company with offices in Mobile and Pensacola, has begun advertis ing for volunteers, offering almost double the rate for most plasma donations.
From donors' plasma, the liquid part of blood, laboratories plan to cull what's known as immune globulin, which may be given to soldiers or others exposed to smallpox in the event of a bioterror attack, according to the company.
The globulin, now in short supply nationwide, has been shown to prevent severe sickness in exposed people, and can aid people who develop complications to the smallpox vaccine. Serologicals is supplying the product to a Canadian company, which has a contract with the federal government.
It's all part of a new national plan to prepare Americans for more terrorism in the wake of the Sept. 11 attacks and subsequent anthrax deaths, said Dr. Keith Ramsey, infectious disease specialist at the University of South Alabama College of Medicine. Ramsey is secretary of the Society for Healthcare Epidemiology, and has provided input to federal authorities about what to expect in bioterrorism attacks.
The country now has only about 700 doses of the immune globulin and hopes to make more than 3,000 available by the end of the year, federal authorities have said.
Smallpox disease, which can cause red welts all over the body, as well as fever, blindness and even death, was declared eradicated from the globe in 1980, after decades of successful vaccinations. But hostile countries, including Iraq, are suspected of keeping some of the virus in storage, according to news reports.
The federal government announced this month that it would soon begin vaccinating as many as 500,000 medical and emergency workers against smallpox, as the safest approach to minimizing spread of the disease.
But it could take months for all of those people to be immunized.
"What if an attack occurs two weeks from now? One way to deal with that is to give exposed people the immune globulin," Ramsey said. The substance helps the body fight off the smallpox virus for about a month. By that time, a vaccine can be given, further boosting the exposed patient's immune system, he said.
Also, most U.S. military personnel have not been immunized for smallpox since the 1980s. The globulin may soon be used to treat exposed troops, a growing concern in light of President Bush's recent talk about a possible war against Iraqi leader Saddam Hussein, some U.S. officials have said.
Participating in the Serologicals program finance.yahoo.com is not necessarily a walk in the park. The smallpox vaccine is a live virus, a cousin to the smallpox microbe. It can produce encepha litis, the symptoms of which include sleepiness, high fever and even death in a small percentage of inoculated people, health officials warn.
That's why the federal government has opted to inoculate only medical and emergency workers, instead of the entire U.S. population -- to minimize the number of people sickened by the vaccine itself.
In the program now under way in Mobile, pregnant women and those who live with pregnant women, as well as people with suppressed immune systems, cannot participate, said Diane Hazelwood, a Serologicals worker.
After participants get the vaccine, they have to return twice a week for two months, for as much as 90 minutes per session, to give plasma. Donating plasma takes longer than giving blood because blood serum is removed, and red cells are returned.
Serologicals is an established company, and produces immune globulin for other diseases. Although many plasma donors historically have been in need of money, the company screens thoroughly for blood-borne diseases and toxins, according to company information.
"Serologicals has a good record," Ramsey said.
Last year, the company, which started in Pensacola in 1971, reported more than $175 million in assets and a net profit of $17 million, according to its financial reports. It is a publicly traded company whose stock has traded between $15 and $21 since Sept. 11.
Serologicals is conducting the immune globulin program at its donor locations around the country, under contract with Cangene Corp., said Connie Graves, donor coordinator for Serological's Mobile office on Airport Boulevard.
al.com </bullboards/wraplink.asp?url=www.al.com/news/mobileregister/index.ssf?/xml/story.ssf/html_standard.xsl?/base/news/1027070224111570.xml>
.---------------------Newer messages....------------
I suspect that even with limited initial production in the year 2002 of the smallpox IgG (2,700 units in the next 4 months) smallpox immune globulin is highly valued and thus should produce relatively significant revenue returns for CNJ over the next several years as production ramps up. (100,000++ units per year?)
The smallpox immune globulin will be a product that will supplement the smallpox vaccine being produced by Cangene's subsidiary Chesapeake Biologics.
---------------------
Notwithstanding that the US federal government announced this month that it would soon begin vaccinating as many as 500,000 medical and emergency workers against smallpox, as the safest approach to minimizing spread of the disease, the US government has contracted for the manufacture of 300 million doses of the smallpox vaccine from the Baxter/Acambis/CBL/Cangene partnership.
The US federal government will then place the majority of the produced vaccine into storage for use if and when necessary.
And the contracting of Cangene by the US governement for the production of smallpox immune globulin appears to now place Cangene amongst the highest in ranking of those companies with the ability to produce biological products as a countermeasure to biological terrorism.
Cangene is begining to carve out a very important niche for itself in its ability to fulfill contract manufacturing requirements for the production of biological products.
stockhouse.com;
.---------------------Newer messages....------------
"These results are in line with record end user demand for WinRho SDF® [Rho (D) Immune Globulin Intravenous (Human)] during the quarter.
"Great for CNJ's upcoming quarterly results. Record demand for WinRhoSDF supplemented with revenues from the US government smallpox contract should spell good things for CNJ and its shareholders this quarter. "
out
---------------------
Investors finally have realized that record end user demand (ie.higher sales) for WinRho SDF® have been recorded by NABI for the quarter. This means higher profits for CNJ this quarter and those going forward.
That explains the fluctuation in the price of the stock reversing back to the upside. The current target on CNJ is $13.50 and this could move up anytime soon.
---------------------
I phoned Cangene. Apparently John Langstaff is on holidays and not back until next week sometime. If any news is about to pop, I would not expect it to happen until he is back from holidays............but I have been wrong before.
---------------------
.....thanks for doing the dirty work (making the call to Mr Langstaff) for us. I think the best buying sign we've had of late were all those insiders buying. If investors could know what insiders were doing all the time, they would make a lot of money. Too bad this stock has been beaten back lately. It was the last one of my stocks to get pummelled during these terrible market conditions. Hope we've bottomed out now. |
